WESTMINSTER, Colo.--(BUSINESS WIRE)--Mar. 31, 2009--
Allos Therapeutics, Inc. (NASDAQ:ALTH) announced today the pricing of an
underwritten public offering of 7,750,000 shares of its common stock.
The Company expects the offering to close on or about April 3, 2009,
subject to customary closing conditions.
UBS Investment Bank is the sole manager for the offering. The Company
has granted the underwriter a 30-day option to purchase up to an
additional 1,162,500 shares to cover over-allotments, if any. The
Company plans to use the net proceeds from the offering primarily for
activities relating to preparations for the potential commercial launch
of pralatrexate, clinical and preclinical research and development of
pralatrexate, working capital and general corporate purposes.
A registration statement relating to these shares was filed with the
Securities and Exchange Commission and declared effective on June 5,
2007. This offering is being made pursuant to a prospectus supplement to
the registration statement. Copies of the prospectus supplement relating
to this offering, when available, may be obtained from UBS Investment
Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY
10171, or by calling (888) 827-7275.
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy the Company's common stock, nor
shall there be any sale of the common stock in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any state.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the treatment of
cancer.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include
statements concerning the completion of the offering, the amount of the
net proceeds, the potential to complete the Company’s ongoing
development programs with the proceeds of the financing, and other
statements which are other than statements of historical facts. In some
cases, you can identify forward-looking statements by terminology such
as "may," "will," "should," "expects," "intends," "plans," anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"continue," and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement is
not forward-looking. Such forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties that
may cause actual results to differ materially from those anticipated by
the forward-looking statements. These risks and uncertainties include,
among others: the risk that the financing may be delayed or may not
occur due to market or other conditions and the risk that additional
capital may be required in the future to complete on-going trials.
Additional information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31,
2008, the Company's other periodic reports and filings with the SEC and
the prospectus supplement related to the offering. The Company cautions
investors not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are
based on information currently available to the Company on the date
hereof, and the Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of this presentation, except as required by law.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 303-426-6262
mgreer@allos.com
